Monoclonal antibodies (mAbs) have emerged as a major class of therapeutic agents on the
market. To date, approximately 80 mAbs have been granted marketing approval. In 2018, 12 …

Monoclonal antibodies (mAbs) are subject to instability issues linked to their protein nature.
In this work, we review the different mechanisms that can be linked to monoclonal antibodies …

Therapeutic protein drugs are an important class of medicines serving patients most in need
of novel therapies. Recently approved recombinant protein therapeutics have been …

Monoclonal antibodies (mAbs) are a crucial asset for human health and modern medicine,
however, the repeated administration of mAbs can be highly immunogenic. Drug …

In a broad investigation into a cause for these 3 events (detailed in Methods in this article's
Online Repository at www. jacionline. org), a clinical database review found no other serious …

Protein-based therapeutics have been revolutionizing the oncology space since they first
appeared in the clinic two decades ago. Unlike traditional small-molecule …

The impact of protein therapeutics in healthcare is steadily increasing, due to advancements
in the field of biotechnology and a deeper understanding of several pathologies. However …

Nowadays, nanotechnology-based modulation of the immune system is presented as a
cutting-edge strategy, which may lead to significant improvements in the treatment of severe …

Atopic dermatitis (AD) is a chronic inflammatory skin disease with pruritus, characterized by
recurrent eczema with exacerbations and remissions. AD impairs patients' QOL and places …

The treatment of some high-incidence human diseases is based on therapeutic cell killing.
In cancer this is mainly achieved by chemical drugs that are systemically administered to …